Trial Site Detail
Drug: |
Sunitinib or Imatinib |
|||
|---|---|---|---|---|
Trial: |
Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors (Resistant at 400 mg Imatinib) |
|||
| Conditions: | Gastrointestinal Stromal Tumor | |||
Trial Status: |
Terminated |
|||
New York Presbyterian Hospital - Columbia University Medical Center622 W 168th St |
Principal Investigator: |
Robert Taub, MD |
|---|---|
Contact: |
|
Activation Status of this Site: |
Closed |
Notes about this Site: |
|
New York Presbyterian Hospital - Columbia University Medical Center Website: |
www. nyp.org |
Navigating the Map
Use the plus (+) and minus (-) controls to zoom in/out.
Click and drag the map or use the arrows to move (pan) the map.
Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.